Funded services in nanopharmaceutical development
First stage application period closed on 28 February 2023
PHOENIX-OITB’s mission is to offer a Single-Entry-Point for a consolidated network of facilities, technologies, services and expertise for all the technology transfer aspects from characterization, testing, verification up to scale-up, GMP compliant manufacturing and regulatory guidance in the field of nanopharmaceutical development, framing the OITB clearly within the nanomedicine field.
The services and expertise provided by the PHOENIX-OITB include production and characterisation under GMP conditions, safety evaluation, regulatory compliance and commercialisation boost. The Open Call will offer funded services in the following categories:
Physico-Chemical Characterisation
Surface Properties, Moisture/Dry, Mass, Size & Distribution, Structure, Morphology, Composition, Chemical Stability, Particle concentration, Drug (API) release kinetics, Free/Encapsuled API Sterility
in vitro Characterisation
Composition, Bioactivity, Immunocompatibility, Immunoresponse, Extraction of targeted cells, (A)cellular reactivity & cytotoxicity, Cell viability, Cel. struct., Uptake & localisation, Inflammatory response, Endocytosis/Exocytosis, Sensitization & Irritation, Cytotoxicity, Genotoxicity, Nanomechanical prop. of cells & tissues, Dose metrics, Microbial evaluation, Transcriptomics, Metabolomics, Proteomics, Gene expression
in vivo Characterisation
Biodistribution, Hemocompatibility, Pharmacokinetics, Pharmacodynamics, Acute, Sub-acute & Repeated, Dose systemic toxicity, Reproductivity toxicity
Manufacturing
Manufacturing of liquid, semi-solid, solid nanoparticle formulations with a special focus on extended release parenterals, lipid based formulations and nanovesicles, liposomes, solid lipid nanoparticles, crystalline nanoparticles, polymeric nanoparticles, inorganic nanoparticles,. On-site lyophilization and fill and finish capabilities.
How to apply
Any legal entity (SMEs, start up or RTOs) and research group, based in the European Union or associate countries of H2020 can apply to this call.
The Evaluation Committee will evaluate each proposal in three main criteria:
- Excellence
- Implementation
- Impact
The applicants will be informed about the decision made by the Evaluation Committee by the end of 03.04.2023 via email. A Stage 2 detailed application must then be submitted by 30.04.2023. Awarded projects must be completed by February 2025.
Application documents
Potential applicants should read ALL supporting documents.
For any questions, please contact open-call@phoenix-oitb.eu
View our Q&A with Scientific Coordinator Dr. Nazende Günday-Türeli here.